A Comprehensive Review of Clinical Cardiotoxicity Incidence of FDA-Approved Small-Molecule Kinase Inhibitors

Numerous protein kinases encoded in the genome have become attractive targets for the treatment of different types of cancer. As of January 2020, a total of 52 small-molecule kinase inhibitors (SMKIs) have been approved by the FDA. With the numerous clinical trials and a heavy focus on drug safety,...

Descripción completa

Detalles Bibliográficos
Autores principales: Jin, Ying, Xu, Zhifei, Yan, Hao, He, Qiaojun, Yang, Xiaochun, Luo, Peihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303342/
https://www.ncbi.nlm.nih.gov/pubmed/32595510
http://dx.doi.org/10.3389/fphar.2020.00891

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303342/
https://www.ncbi.nlm.nih.gov/pubmed/32595510
http://dx.doi.org/10.3389/fphar.2020.00891

Ejemplares similares